Mucolytic agent

A mucolytic agent is a pharmacological class of drugs rather than a single biological target molecule [StatPearls: NBK534832]. These agents are primarily used to treat respiratory conditions characterized by excessive or highly viscous mucus production, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchiectasis [Balsamo et al., 2010; PMC3000625]. Their primary function is to alter the physical properties of mucus, specifically by decreasing its viscosity and elasticity to facilitate easier clearance from the respiratory tract via the mucociliary escalator or coughing [Rogers, 2007; PMID 17654523]. Mechanistically, many of these drugs target the disulfide bonds within mucin glycoproteins (primarily MUC5AC and MUC5B) or digest extracellular DNA accumulated from degraded neutrophils [Bryson and Sorkin, 1994; PMID 7525166]. By improving airway clearance, mucolytic agents help reduce the frequency of exacerbations and improve overall respiratory function and quality of life in affected patients [StatPearls: NBK534832]. Because the term describes a therapeutic category rather than a specific receptor, enzyme, or transporter, it is considered a drug class name rather than a biological target [NIH: MeSH D009292].

Other names

MucolyticsSecretolyticsMucus-thinning agentsMucoactive agents

Mucolytic agents work through several distinct biochemical mechanisms. Classic mucolytics, such as N-acetylcysteine, contain free sulfhydryl groups that facilitate a sulfhydryl-disulfide interchange, reducing the disulfide bonds between mucin monomers and breaking down the complex three-dimensional gel matrix of mucus [StatPearls: NBK534832; Rogers, 2007]. Peptide mucolytics, exemplified by dornase alfa (recombinant human DNase I), enzymatically cleave extracellular DNA present in the thick, purulent secretions of patients with cystic fibrosis [Bryson and Sorkin, 1994]. Other agents, such as carbocisteine, act as 'mucoregulators' by influencing the intracellular synthesis of mucins and altering the ratio of sialomucins to sulfomucins, thereby producing less viscous secretions [Balsamo et al., 2010; PMC3000625].